Viridian Therapeutics
VRDN
132 hedge funds and large institutions have $1.32B invested in Viridian Therapeutics in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 49 increasing their positions, 43 reducing their positions, and 16 closing their positions.
900% more funds holding in top 10
Funds holding in top 10: 1 → 10 (+9)
214% more call options, than puts
Call options by funds: $1.85M | Put options by funds: $590K
72% more capital invested
Capital invested by funds: $770M → $1.32B (+$551M)
56% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 16
14% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 43
7% more funds holding
Funds holding: 123 → 132 (+9)
0.51% more ownership
Funds ownership: 114.85% → 115.36% (+0.51%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$116M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
+$36.7M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$17.6M |
| 4 |
VA
VR Adviser
New York
|
+$12.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$30.8M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$22.3M |
| 3 |
Millennium Management
New York
|
-$18.2M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$10.4M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$9.79M |
VRDN Hedge Fund Activity: Q4 2023 in Review
132 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2023, worth a combined $1.32B — up 72% from $770M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new VRDN positions and 16 closed out — a net gain of 9 holders — while 49 added to existing stakes and 43 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $116M. The largest seller was RA Capital Management, exiting entirely with an estimated $30.8M sold.
- 132 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2023, up from 123 in Q3 2023.
- Funds reported $1.32B of Viridian Therapeutics stock for Q4 2023, up 72% quarter-over-quarter.
- 25 funds opened new Viridian Therapeutics positions in Q4 2023 and 16 closed out, a net change of +9 holders.
- The largest Viridian Therapeutics buyer in Q4 2023 was Fidelity Investments, an estimated $116M added.
- The largest Viridian Therapeutics seller in Q4 2023 was RA Capital Management, an estimated $30.8M sold.
Based on aggregated 13F filings for Q4 2023.